Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer.

Tomoyasu YoshihiroHitoshi KusabaAkitaka MakiyamaKazuma KobayashiMasato UenomachiMamoru ItoYasuhiro DoiKenji MitsugiTomomi AikawaKotoe TakayoshiTaito EsakiHozumi ShimokawaKenji TsuchihashiHiroshi AriyamaKoichi AkashiEishi Baba

Published in: International journal of clinical oncology (2019)

Low RDI did not compromise the treatment efficacy of ramucirumab plus modified FOLFIRI for MCRC patients.

Keyphrases

metastatic colorectal cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
combination therapy